Skip to content

Clinical trials

Mucopolysaccharidosis I trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Mucopolysaccharidosis I Country / region: United States Clear all

53 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20031
20042
20052
20061
20071
20087
20094
20101
20112
20122
20131
20145
20152
20172
20184
20192
20203
20211
20222
20233

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed26
Terminated13
Active, not recruiting5
Recruiting4
No longer available1
Suspended1
Enrolling by invitation1
Unknown status1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Masonic Cancer Center, University of Minnesota9
Genzyme, a Sanofi Company4
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center3
Patricia I. Dickson, M.D.3
University of Minnesota3
JCR Pharmaceuticals Co., Ltd.2
Magenta Therapeutics, Inc.2
Paul Szabolcs2
REGENXBIO Inc.2
Sangamo Therapeutics2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Mucopolysaccharidosis I53
Mucopolysaccharidosis II17
Mucopolysaccharidosis VI16
Mucopolysaccharidoses14
Leukodystrophy, Globoid Cell13
Leukodystrophy, Metachromatic13
Metabolism, Inborn Errors9
Adrenoleukodystrophy8
Sudden Infant Death8
Fucosidosis7

Trials

Showing 1 to 25 of 53. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.